(firstQuint)A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis.

 The study will evaluate the 3-drug combination of lenalidomide; melphalan; and dexamethasone (MDR) as the absence of disease progression or toxicity, patients will complete nine 28-day cycles of MDR therapy, with the option of continuing treatment with lenalidomide as single-agent.

 Patients received up to nine cycles of treatment, with the option to continue on lenalidomide as a single agent if they responded to treatment.

.

 A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis@highlight

This open-label trial will evaluate the use of lenalidomide; melphalan; and dexamethasone (MDR) to treat newly diagnosed or relapsed AL amyloidosis, over the course of nine 28-day cycles.

